Evaluation of p63 and p73 antibodies for cross-reactivity

Cell Cycle

Volumn 8, Issue 22, 2009, Pages 3702-3706

  Rosenbluth, Jennifer M ^a   Johnson, Kimberly ^a   Tang, Luojia ^a   Triplett, Tracy ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

4A4; IMG 259; Immunofluorescence; Immunohistochemistry; Isoforms

Indexed keywords

ANTIBODY; P63 ANTIBODY; P73 ANTIBODY; PROTEIN P63; PROTEIN P73; REAGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CROSS REACTION; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; PROTEIN EXPRESSION;

EID: 70449934570     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.22.10036     Document Type: Article

References (28)

1. Rosenbluth JM, Pietenpol JA. mTOR regulates autophagy-associated genes downstream of p73. Autophagy 2009; 5.
2. Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes & development 2008; 22:2591-2595
3. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 2008; 11:152-163
4. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 2006; 12:3922-3927
5. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. The Journal of clinical investigation 2007; 117:1370-1380 (Pubitemid 46718425)
6. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast cancer research and treatment 2001; 66:183-190 (Pubitemid 32675020)
7. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53 and E2F-1. J Clin Oncol 2006; 24:805-815 (Pubitemid 46622048)
8. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11:8372-8383 (Pubitemid 41746950)
9. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell cycle (Georgetown, Tex) 2007; 6:1995-2000.
10. Concin N, Becker K, Slade N, Erster S, Mueller- Holzner E, Ulmer H, et al. Transdominant DeltaTAp73 isoforms are frequently upregulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64:2449-2460
11. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 1999; 6:389-390 (Pubitemid 29245951)
12. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/ p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13:962-972 (Pubitemid 43753487)
13. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188:1763-1768 (Pubitemid 28516121)
14. Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 1999; 18:4993-4998 (Pubitemid 29425306)
15. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399:806-809 (Pubitemid 29293179)
16. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14:743-751 (Pubitemid 46444512)
17. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004; 279:44713-44722 (Pubitemid 39430881)
18. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9:45-56. (Pubitemid 43069510)
19. Deyoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-Specific p73 Upregulation Mediates p63 Dependence in Squamous Cell Carcinoma. Cancer Res 2006; 66:9362-9368 (Pubitemid 44623630)
20. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 1999; 274:18709-18714 (Pubitemid 129519278)
21. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. The Journal of cell biology 1988; 106:761-771 (Pubitemid 18089976)
22. Niemantsverdriet M, Vermeij WP, Backendorf C. RT-PCR analysis of p73 splice variants, ease or tease? Leukemia 2005; 19:1685-1686
23. Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res 2005; 65:2314-2320 (Pubitemid 40490141)
24. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9:897-903. (Pubitemid 28514285)
25. Liu G, Nozell S, Xiao H, Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004; 24:487-501. (Pubitemid 38057903)
26. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities. Molecular cell 1998; 2:305-316
27. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008; 28:5951-5964
28. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276:15164-15173 (Pubitemid 37373402)